About this item
Over the past 20 years, the biomedical research community has been delivering hundreds of breakthroughs expected to extend human lifespan beyond thresholds imaginable today. However, much of this research has not yet been adopted into clinical practice, nor has it been widely publicized. Biomedicine will transform our society forever by allowing people to live longer and to continue working and contributing financially to the economy longer, rather than entering into retirement and draining the economy through pensions and senior healthcare. Old age will become a concept of the past, breakthroughs in regenerative medicine will continue, and an unprecedented boom to the global economy, with an influx of older able-bodied workers and consumers, will be a reality.
About the Author
Alex Zhavoronkov, PhD, is the director and a trustee of the Biogerontology Research Foundation, a UK-based think tank supporting aging research worldwide and is the founder of the International Aging Research Portfolio, a curated knowledge management system for aging research. He heads the laboratory of regenerative medicine at the Clinical Research Center for Pediatric Hematology, Oncology and Immunology where his research interests include Hutchinson-Gilford Syndrome, new methods of cellular reprogramming, molecular mechanisms of skin and cartilage regeneration and personalized medicine in oncology. He is also the international adjunct professor at the Moscow Institute of Physics and Technology. Together with scientists from Canada, Russia and the US, he co-founded the First Oncology Research and Advisory Center, a personalized medicine organization providing contract research services to oncologists interested in gene expression and activated signalling pathway analysis and predicted effectiveness of targeted drugs to improve clinical decision making.He is also the head of research at NeuroG Neuroinformatics, a neuroinformatics company developing algorithms for cost-effective EEG devices to recognize imagined visual images and delay the onset of age-related neurodegenerative diseases.He holds two bachelor degrees from Queen's University, a masters in biotechnology from Johns Hopkins Universtity and a PhD in physics and mathematics from the Moscow State University.
